TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05176171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive Keratectomy with Corneal Cross-Linking
Description: To our knowledge, this study is one of the first to compare the visual results of non-topography-guided and topography-guided photorefractive keratectomy (PRK) applying sequential and simultaneous corneal cross-linking (CXL) treatment for keratoconus. Considering recent advances in cross-linking and imaging in keratoconus, the outcomes of this study can lead us to several non-invasive algorithm management options.
Study: NCT01651806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid standard dose
Description: Uniform 1 gram dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Females Tranexamic Acid weighted dose
Description: Weighted dose--20mg/kg of the drug will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Females receiving a uniform dose of TA
Description: Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Males Weighted Dose TA
Description: Weighted dose--20mg/kg of the drug will be given
Study: NCT01936090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: Undergo autologous bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01386970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine 300mg and lamivudine 150mg as Combivir
Description: twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine 300mg and lamivudine 150mg as Combivir
Description: twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
Study: NCT02511223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLAPARIB
Description: Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
Study: NCT01210040

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 2.8mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid and Iron
Description: 60mg Iron and 2.8mg Folic Acid
Study: NCT04135586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Yoga + educational program
Study: NCT00229424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lafutidine
Description: Oral administration of lafutidine by 20mg/day along with famotidine placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Oral administration of famotidine by 40mg/day along with lafutidine placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of lafutidine placebo along with famotidine placebo
Study: NCT01049009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol XL
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol XL
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.
Study: NCT01049542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astressin 2B
Description: After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
Study: NCT03843671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric oxygen
Description: Hyperbaric oxygen therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric chamber
Description: Hyperbaric chamber
Study: NCT02770937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality simulator
Description: The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Box trainer
Description: The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simbionix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simbionix
Study: NCT02792803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo-Latanoprost
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo-Latanoprost
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Latanoprost
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Latanoprost
Description: A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
Study: NCT02450487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
Study: NCT01790048

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey permeate RUSF
Description: Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Protein RUSF
Description: Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources.
Study: NCT01562548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: high and low dose of Guaifenesin each given twice daily over a 4-day treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: high and low dose of Guaifenesin each given twice daily over a 4-day treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active ingredient
Study: NCT04226404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-11
Description: Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-12
Description: Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-13
Description: Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-14
Description: Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-15
Description: Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-16
Description: Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD1905-17
Description: Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
Study: NCT02926209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aer-O-Scope (Colonoscopy)
Description: Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aer-O-Scope (Colonoscopy)
Description: Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy (Conventional Colonoscope)
Description: Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy (Conventional Colonoscope)
Description: Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope
Study: NCT03690765

Intervention type: DRUG
Intervention: Duphaston® (Dydrogesterone)
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.

Intervention type: DRUG
Intervention: Duphaston® (Dydrogesterone)
Description: No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
Study: NCT00209339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (MitraClip Implant)
Description: Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
Study: NCT02798796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: All patients will be submitted to MRI
Study: NCT04995393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heating with a disposable glove containing water
Description: Heating of the infants heel with a glove before blood sampling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heating with a blanket
Description: Heating of the infants heel with a blanket before blood sampling.
Study: NCT03843671

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric chamber
Description: Hyperbaric chamber
Study: NCT02036970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bardoxolone methyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02535156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Risperidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose Placebo
Study: NCT01254162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTC896 Gel
Description: 0.75% w/w gel applied daily for 28 days to the forehead
Study: NCT03613142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double tract anatomosis
Description: After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastrostomy
Description: After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
Study: NCT02011724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Study: NCT03671317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Clowning
Description: This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
Study: NCT04364984

Intervention type: DRUG
Intervention: Angiotensin converting enzyme inhibitor
Description: routine drug intake

Intervention type: DRUG
Intervention: Angiotensin Receptor Blockers
Description: routine drug intake

Intervention type: DRUG
Intervention: Direct renin inhibitor
Description: routine drug intake
Study: NCT00926029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Brush twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal salt
Description: Brush twice daily
Study: NCT04582253

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterior and posterior surfaces of the cornea to obtain corneal tomographic maps.
Study: NCT01217333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person CP
Description: CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-CP
Description: Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
Study: NCT01786070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01068600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Once daily via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Once daily via SDDPI
Study: NCT04078256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise program
Description: Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual training routine
Description: The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
Study: NCT04316091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy+SPIONs/SMF
Description: Intratumoral injection of SPIONs, followed by SMF, combined with conventional neoadjuvant chemotherapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: neoadjuvant chemotherapy
Description: Conventional neoadjuvant chemotherapy only
Study: NCT02535390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action based cognitive remediation
Description: This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
Study: NCT03691194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fresh orange juice
Description: The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: concentrated orange juice
Description: The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
Study: NCT00880971

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative 3D-CRT or IMRT
Description: Postoperative radiotherapy using 3D-CRT or IMRT techniques, 2 Gy per fraction, total 25 fractions (50Gy) over 5 weeks.